Karyopharm Therapeutics (KPTI) Adds New Director
Tweet Send to a Friend
Karyopharm Therapeutics (NASDAQ: KPTI) announced the appointment of Mikael Dolsten, MD, PhD, President of Pfizer Worldwide Research and Development of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE